Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020160226 - PROCÉDÉ DE TRAITEMENT ET/OU DE PRÉVENTION DE LA LYSE DE BACTÉRIOPHAGES PENDANT LA FERMENTATION

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

What is claimed:

1. A method of cultivating a bacterial strain and/or producing a growth by-product of a

bacterial strain, the method comprising:

a) inoculating a nutrient medium with the strain;

b) applying an antiviral composition to the nutrient medium; and

c) cultivating the strain to produce a culture having a desired cell density and/or a

desired concentration of the growth by-product,

wherein the antiviral composition comprises one or more antiviral compounds that

interfere with viral DNA or RNA synthesis and/or interfere with viral DNA or RNA

polymerase activity, and

wherein the antiviral composition controls a bacteriophage in the culture but does not

harm the bacterial strain.

2. The method of claim 1, wherein the antiviral composition comprises ribavirin.

!

3. The method of claim 1, wherein the bacteria is a strain of Bacillus , Azotobacter,

Pseudomonas or Rhodococcus.

4. The method of claim 1, wherein the nutrient medium is solid or liquid.

5. The method of claim 1, wherein the nutrient medium comprises sources of nitrogen

and carbon.

6. The method of claim 1, wherein about 0.5 g/L to about 10.0 g/L of the antiviral

composition is applied to the nutrient medium.

7. The method of claim 1, wherein the antiviral composition is applied prior to, or

concurrently with, inoculating the nutrient medium.

8. The method of claim 1, wherein the antiviral composition is applied after inoculating

the nutrient medium.

9. The method of claim 1, further comprising testing the culture for the presence of a bacteriophage infection.

10. The method of claim 9, wherein, if a bacteriophage infection is detected, the method further comprises applying one or more additional applications of the antiviral composition.

11. The method of claim 1 , wherein the antiviral composition comprises one or more of ribavirin, valacyclovir, acyclovir, famciclovir, ganciclovir, valganciclovir, brivudin, cidofovir, fomivirsen, foscamet, penciclovir, vidarabine, favipiravir, galidesivir, remdesivir, mericitabine, moroxydine, triazavirin, asunaprevir, boceprevir, ciluprevir, danoprevir, faldaprevir, glecaprevir, grazoprevir, narlaprevir, paritaprevir, simeprevir, sovaprevir, telaprevir, vaniprevir, vedroprevir, voxilaprevir, daclataasvir, elbasvir, ledipasvir, odalasvir, ombitasvir, pibrentasvir, ravidasvir, ruzasvir, samatasvir, velpatasvir, beclabuvir, dasabuvir, deleobuvir, filibuvir, setrobuvir, sofosbuvir, radalbuvir, uprifosbuvir, pleconaril, umifenovir, adapromione, amantadine, rimantadine, oseltamivir, zanamivir, peramivir, and laninamivir.

12. The method of claim 1, wherein the bacteriophage is from Cystoviridae or Leviviridae.